Brief Report: Real-World Treatment Patterns and Clinical Outcomes for Patients With Advanced ALK-Rearranged NSCLC in British Columbia
Introduction: EML4-ALK rearrangements represent an oncogenic driver alteration in 5% of NSCLC cases. We aim to better understand real-world treatment patterns and outcomes of ALK fusion-positive (ALK+) patients with advanced-stage NSCLC. Methods: We performed a retrospective population-based chart r...
Saved in:
| Main Authors: | Peiyao Wang, BSc, Curtis Hughesman, PhD, Stephen Yip, MD, PhD, FRCPC, William W. Lockwood, PhD, Sophie Sun, MD, MSc, FRCPC |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364324000675 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA
by: Simon Heeke, PhD, et al.
Published: (2025-04-01) -
Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada
by: Lara Chayab, et al.
Published: (2024-12-01) -
Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China
by: Zhujun Chen, et al.
Published: (2025-07-01) -
Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
by: Athanasios R Paliouras, et al.
Published: (2020-06-01) -
Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience
by: Claudia Parisi, et al.
Published: (2024-12-01)